Table 2 Posterior estimates and contrasts for primary and secondary outcomes
| Â | Default priors | Informative priors | ||||
|---|---|---|---|---|---|---|
% pill counts (logit-scale) | Median | 95% CI | Median | 95% CI | ||
Intercept | 2.69 | 1.29 | 4.06 | 2.52 | 1.39 | 3.66 |
 MPH | 0.06 | −1.85 | 1.90 | 0.39 | −0.89 | 1.79 |
Visit Week 4 | −0.13 | − 0.68 | 0.42 | − 0.25 | − 0.8 | 0.24 |
Visit Week 8 | −0.15 | −0.74 | 0.42 | −0.3 | − 0.83 | 0.22 |
MPH-by-Week 4 | −0.66 | −1.47 | 0.15 | −0.5 | −1.22 | 0.25 |
MPH-by-Week 8 | −1.07 | −1.89 | −0.23 | −0.92 | − 1.63 | −0.17 |
Pr (MPH > placebo) | ||||||
 Week 2 | 0.526 |  |  | 0.713 |  |  |
 Week 4 | 0.265 |  |  | 0.434 |  |  |
 Week 8 | 0.144 |  |  | 0.250 |  |  |
% MEMS caps (logit-scale) | Median | 95% CI | Median | 95% CI | ||
 Intercept | 2.75 | 1.41 | 4.2 | 2.51 | 1.3 | 3.54 |
  MPH | −0.16 | − 2.09 | 1.71 | 0.37 | −0.98 | 1.72 |
 Visit Week 4 | −0.45 | −1.04 | 0.09 | −0.47 | −1 | 0.02 |
 Visit Week 8 | −0.56 | − 1.17 | 0.01 | −0.62 | − 1.13 | − 0.09 |
MPH-by-Week 4 | 0.21 | −0.6 | 1.01 | 0.18 | −0.53 | 0.88 |
MPH-by-Week 8 | −0.64 | −1.45 | 0.19 | −0.64 | −1.36 | 0.09 |
Pr (MPH > placebo) | ||||||
 Week 2 | 0.442 |  |  | 0.698 |  |  |
 Week 4 | 0.522 |  |  | 0.773 |  |  |
 Week 8 | 0.209 |  |  | 0.356 |  |  |